INVESTOR RELATIONS

PRESS RELEASES

2-Dec-2009 AMARIN CORPORATION APPOINTS INDUSTRY VETERAN JOSEPH ZAKRZEWSKI AS EXECUTIVE CHAIRMAN
23-Nov-2009 AMARIN ANNOUNCES NOTICE OF ANNUAL GENERAL MEETING
13-Nov-2009 AMARIN CORP IS FIRST SMALL BIOPHARMACEUTICAL COMPANY TO JOIN SAFE-BIOPHARMA ASSOCIATION
6-Nov-2009 AMARIN APPOINTS JOHN F. THERO AS CHIEF FINANCIAL OFFICER
19-Oct-2009 AMARIN APPOINTS MEDPACE AS CRO FOR TWO PHASE 3 CARDIOVASCULAR TRIALS
19-Oct-2009 AMARIN ANNOUNCES COMPLETION OF $70 MILLION PRIVATE PLACEMENT
13-Oct-2009 AMARIN ANNOUNCES CHANGES TO ITS BOARD AND MANAGEMENT TEAM
13-Oct-2009 AMARIN ANNOUNCES $70 MILLION PRIVATE PLACEMENT
5-Oct-2009 AMARIN RECEIVES EXTENSION FROM NASDAQ TO FILE ITS 2008 ANNUAL REPORT ON FORM 20-F
1-Oct-2009 AMARIN ANNOUNCES EXTENSION TO BRIDGE FINANCING
3-Aug-2009 AMARIN ANNOUNCES $3.0 MILLION BRIDGE FINANCING
22-Jul-2009 Amarin Announces Revision To Non-Binding Term Sheet For Private Placement Of Up To $55 Million
9-Jul-2009 Amarin Receives Special Protocol Assessment Agreement From The FDA For Phase 3 Trial In Mixed Dyslipidemia
7-Jul-2009 Amarin Receives NASDAQ Notification Related To Late Filing Of 2008 Annual Report On Form 20-F
7-Jul-2009 Amarin Announces Signing Of Non-Binding Term Sheet For Private Placement Of Up To $55 Million
1-Jul-2009 Amarin Reports Preliminary Unaudited Financial Results For The Six And Twelve Months Ended December 31, 2008
10-Jun-2009 Amarin Announces Results From Exploratory Phase 2a Study Of EN101 In Myasthenia Gravis
26-May-2009 Amarin Announces $2.6 Million Bridge Financing
6-May-2009 Amarin Receives Special Protocol Assessment Agreement From The FDA For Phase 3 Cardiovascular Trial
8-Apr-2009 Amarin's Marketing Authorization Application for AMR101 to Treat Huntington's Disease Accepted for review by EMEA
Page 1 of 2